An Opportunity to Review More Than 50 Companies From Various Elements of the Bioprocessing Industry.DUBLIN, Ireland -- Since the original discoveries of the 1970s, the use of recombinant DNA technology recombinant DNA technology Recombining of DNA molecules from two different species that are inserted into a host organism to produce new genetic combinations that are of value to science, medicine, agriculture, or industry. has led to the creation of a biotechnology industry which, in the US, now comprises more than 1,500 companies, of which 363 are public companies, with revenues just over $72 billion and employing more than 146,100 people. Europe represents about 17% of the global market, with 1,600+ companies employing 68,000 people and with revenues approximating $12 billion. The Asia/Pacific region has 700+ companies, employing 12,000 people and with revenues of $2 billion. Most of these companies worldwide are researching, developing, and manufacturing biopharmaceuticals. Research and Markets (http://www.researchandmarkets.com/reports/c40417) has announced the addition of The Bioprocessing Industry: Increasing Capacity, Production, and Efficiency, 2nd Edition to their offering. "The Bioprocessing Industry: Increasing Capacity, Production, and Efficiency, 2nd Edition" marketing analysis report presents a thorough and organized analysis of this critical industry and its major components. This report covers the most important issues in bioprocessing including the threat of a significant shortage in manufacturing capacity, consolidation in key sectors of the industry and the next drug discovery trends fueling expansion. In addition, more than 50 companies from various elements of the bioprocessing industry are profiled in depth. This report provides a comprehensive review of the bioprocessing industry and its major components. It focuses on those companies with a large stake in the overall success of the biopharmaceutical business, or those with a particular product or technology that offers significant advantages over competing products. Profiles of companies within the industry are included and consist of a summary of information obtained from the Scrip Pharmaceutical Companies Fact File database including corporate headquarters and locations, principals, licensing information, mergers & acquisitions, projects in R&D, products, financials, and corporate news. One sector of the media business that is experiencing change is the supply of animal blood serum-based media supplements, especially fetal bovine serum Fetal bovine serum ( or foetal bovine serum) is serum taken from the fetuses of cows. Fetal Bovine Serum (or FBS) is the most widely used serum in the culturing of cells. In some papers the expression foetal calf serum is used. . There has been a drive toward the use of serum-free media to improve safety and reduce processing. This international business is split between two major players, Invitrogen and HyClone, and about four smaller suppliers. Capital equipment represents about 40% of the cost of a new GMP GMP (guanosine monophosphate): see guanine. facility. In this market sector, there has been significant condensation, in which multifirm companies are still acquiring smaller companies and adding to their product range and geographical coverage. Examples include the SP Industries conglomerate, which now contains both major US manufacturers of lyophilizers and Thermo Electron Thermo Electron Corporation (TMO (NYSE)) (incorporated 1956) is a major provider of analytical instruments and services for a variety of domains. Thermo has revenues of over $2 billion, and employs 11,000 people in 30 countries. in the centrifuge centrifuge (sĕn`trəfy j), device using centrifugal force to separate two or more substances of different density, e.g., two liquids or a liquid and a solid. market. To a certain extent, this has reduced competition,
although most operations still promote specific product ranges under
their original brand names. The world market for the pilot to
production-scale bioreactors and fermentors is estimated at $380
million, but it fluctuates widely, since capital expenditure on large
custom plants can represent this figure from one installation, but this
is not an annual event. Only three companies are of any importance in
this business, New Brunswick New Brunswick, province, CanadaNew Brunswick, province (2001 pop. 729,498), 28,345 sq mi (73,433 sq km), including 519 sq mi (1,345 sq km) of water surface, E Canada. , B. Braun (now a member of the Sartorius Group), and BioEngineering bioengineering Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (see . Since the technologies are also applicable to other industries, estimates of the value of the bioprocessing industry to the manufacturers of centrifuges, homogenizers, mills, and filter holders is difficult, but since one piece of major equipment may sell for $250,000 to $1 million, and a custom plant may cost several millions of dollars, the bioprocessing "hardware" market must be of the order of $100-500 million. However, manufacturers of large sterile disposable containers and accessories are promoting a trend away from the static tank/pipe type of installation. On a scale of perhaps up to 500 L per batch, this trend may already be having an effect. The trend is likely to trend continue, and the growth of the supply of this type of equipment could be of the order of 10-15% per annum Per annum Yearly. , at the expense of the more traditional stainless steel stainless steel: see steel. stainless steel Any of a family of alloy steels usually containing 10–30% chromium. The presence of chromium, together with low carbon content, gives remarkable resistance to corrosion and heat. plant. Nalge Nunc, Inc., markets a wide range of smaller, disposable cell culture vessels and other plastic disposables. Average annual sales are about $300 million. Becton Dickinson BD (NYSE: BDX), is a medical technology company that manufactures and sells medical devices, instrument systems and reagents. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs 27,000 people in nearly 50 countries. and Co. market the competing "Falcon" range and claim a similar market share. In the chromatographic chro·mat·o·graph n. An instrument that produces a chromatogram. tr.v. chro·mat·o·graphed, chro·mat·o·graph·ing, chro·mat·o·graphs To separate and analyze by chromatography. separations sector, GE Healthcare GE Healthcare is a $18 billion (USD) unit of General Electric (GE). It employs more than 46,000 people worldwide and is headquartered in Chalfont St. Giles, Buckinghamshire, United Kingdom. GE Healthcare is the first GE business segment headquartered outside the United States. (formally Amersham Biosciences) leads the field, but there are at least fifteen other companies with appreciable ap·pre·cia·ble adj. Possible to estimate, measure, or perceive: appreciable changes in temperature. See Synonyms at perceptible. market shares. Total AB sales are around $980 million per annum, with "separations" (principally chromatography chromatography (krō'mətŏg`rəfē), resolution of a chemical mixture into its component compounds by passing it through a system that retards each compound to a varying degree; a system capable of accomplishing this is called a equipment and media) yielding approximately $400 million of this. Other major players in this sector report revenues between $50 million and $100 million. This is possibly the most valuable bioprocessing sector, especially in terms of its consumables, but that position may be held by the filter business. The Companies Mentioned inside this Report include: Abgenix Becton Dickinson Boehringer Ingelheim CSL DSM Anti-Infectives Dyax GE Healtcare GTC Biotherapeutics Invitrogen Large Scale Biology Neose Technologies PPL Therapeutics ProMetic Life Sciences Tosoh Corporation West Pharmaceutical Services For more information visit http://www.researchandmarkets.com/reports/c40417 |
|
||||||||||||||

j)
Printer friendly
Cite/link
Email
Feedback
Reader Opinion